Clinical Trials Browser

Phase 3 × Carcinoma, Non-Small-Cell Lung × osimertinib × Clear all

NCT06417814 2026-03-02

TROPION-Lung15

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-02-27

LAURA

Phase 3 Active not recruiting

216 enrolled 25 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-02-04

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04765059 2026-01-13

COMPEL

Phase 3 Active not recruiting

98 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT05120349 2026-01-12

ADAURA2

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06670196 2025-12-05

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06350097 2025-11-17

TROPION-Lung14

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04035486 2025-10-10

FLAURA2

Phase 3 Active not recruiting

587 enrolled 44 charts 2 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06838273 2025-09-24

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04351555 2025-05-23

NeoADAURA

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05015608 2025-05-23

SACHI

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06829459 2025-04-08

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06486142 2024-07-03

ERIS

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06093503 2024-06-26

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT06380348 2024-04-23

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04816214 2024-03-05

GEOMETRY-E

Phase 3 Terminated

6 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05104281 2023-03-29

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Phase 3 Unknown

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02972333 2016-11-23

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Phase 3 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung